Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
28.08 USD | -1.77% | -4.69% | -2.97% |
01:14pm | Pfizer's Paxlovid Failed to Show Clear Benefits Among Long-COVID Patients in Stanford Study | MT |
Jun. 08 | US FDA expands GSK's RSV vaccine approval to adults aged 50 to 59 | RE |